Silvia Illamola, PharmD, PhD

Research Associate, Birnbaum Lab, Department of Experimental and Clinical Pharmacology (ECP)
Silvia Illamola


Office Phone


Research Associate, Birnbaum Lab, Department of Experimental and Clinical Pharmacology (ECP)
Adjunct Assistant Professor, Department of Experimental and Clinical Pharmacology (ECP)


Laboratory Medicine and Pathology, Universitat Autònoma de Barcelona, Barcelona, Spain

Clinical Pharmacology in Pediatrics, University of Utah, Salt Lake City, Utah, USA

PhD, Universitat de Barcelona

Masters in Design and Statistics in Health Sciences, Universitat Autònoma de Barcelona, Barcelona, Spain

PharmD, Universitat de Barcelona

Expand all


Sílvia M. Illamola (Pharm.D., Ph.D.) is Research Associate at University of Minnesota. She received her PhD from University of Barcelona, and trained as a clinical pharmacologist at the University of Utah. Current research is focused on the clinical pharmacology and pharmacometrics in special populations. Of special interest is the influence of growth and development of often used medication on the pharmacokinetics and pharmacodynamics in newborns, children and infants, and the clinical pharmacology of medications during pregnancy and lactation.


Pharmacometrics, Clinical Pharmacology, pharmacokinetics/pharmacodynamics

Professional Associations

American College of Clinical Pharmacy


  • Catalan
  • French
  • Spanish

Research Summary/Interests

  • Pharmacometrics
  • Clinical Pharmacology
  • Pediatrics
  • Pregnancy
  • Special populations
  • Cystic Fibrosis
  • Infectious Diseases

Research Methods/Techniques

Population pharmacokinetics/pharmacodynamics;LC-MS/MS;LC-MS

Academic Interests and Focus

Pharmacometrics, Clinical pharmacology

Teaching Areas

Pharmacometrics, Clinical pharmacology


  • ECP 8983: Scientific Communications in Experimental and Clinical Pharmacology. Manuscripts: Research Papers and Review Articles. University of Minnesota (2021 - ).
  • ECP 8983: Scientific Communications in Experimental and Clinical Pharmacology. Scientific Writing Basics. University of Minnesota (2021 - ).
  • Neonatology Fellowship conferences: Principles of Pharmacokinetics & Developmental Changes in Neonates. Department of Pediatrics. University of Minnesota (2020 - ).
  • ECP 5220: Regulatory Issues in Drug Research. Laboratory regulation, certifications, GLP. University of Minnesota (2020 - ).


  • Infectious Diseases

Research Funding Grants

Optimal vancomycin exposure target for pulmonary exacerbations in CF (Cystic Fibrosis Foundation)


Illamola SM, Sherwin CM, van Hasselt JGC. Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses. Clin Pharmacokinet. 2018 Oct;57(10):1217-1228.

Illamola SM, Huynh HQ, Liu X, Bhakta ZN, Sherwin CM, Liou TG, Carveth H, Young DC. Population pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrob Agents and Chemother. 2018 Sep 24;62(10).

Valade E, Bouazza N, Lui G, Illamola SM, Benaboud S, Treluyer JM, Cobat A, Foissac F, De Sousa Mendes M, Chenevier-Gobeaux C, Suzan-Monti M, Rouzioux C, Assoumou L, Viard JP, Urien S, Ghosn J, Hirt D. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients. Antimicrob Agents Chemother. 2017 Feb 23;61(3).

Foissac F, Blume J, Tréluyer JM, Tylleskär T, Kankasa C, Meda N, Tumwine JK, Singata-Madiki M, Harper K, Illamola SM, Bouazza N, Nagot N, Van de Perre P, Blanche S, Hirt D. Are Prophylactic and Therapeutic Target Concentrations Different? the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding. Antimicrob Agents Chemother. 2017 Jan 24;61(2).

Illamola SM, Valade E, Hirt D, Dulioust E, Wolf JP, Tréluyer JM. Development and validation of a LC-MS/MS method for the quantification of tenofovir and emtricitabine in seminal plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:234-41.

Illamola SM, Colom H, van Hasselt J.G. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Br J Clin Pharmacol. 2016 Sep;82(3):793-805.

Valade E, Tréluyer JM, Illamola SM, Bouazza N, Foissac F, De Sousa Mendes M, Lui G, Chenevier-Gobeaux C, Suzan-Monti M, Rouzioux C, Assoumou L, Viard JP, Hirt D, Urien S, Ghosn J. Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 Study. Antimicrob Agents Chemother.

Fauchet F, Tréluyer JM, Illamola SM, Pressiat C., Lui G., Valade E., Mandelbrot L, Lechedanec J, Delmas S, Blanche S, Warszawsji J, Urien S, Tubiana R, Hirt D. Population Approach to analyze the pharmacokinetics of free and total Lopinavir in HIV-infected pregnant women and consequences on dose adjustment. Antimicrob Agents Chemother. 2015 Sep; 59(9):5727-35.

Illamola SM, Labat L, Benaboud S, Tubiana R, Tréluyer JM, Hirt D. Determination of total and unbound concentration of lopinavir in plasma. Validation of LC-MS/MS assay and an ultrafiltration method. Journal of Chromatography B. 2014 Aug 15; 965: 216-23.

Illamola SM, Hirt D, Tréluyer JM, Urien S, Benaboud S. Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines. Drug Discovery Today. 2015 Apr; 20(4):466-74.